CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new metallodrugs that utilize red or near-infrared light for targeted cancer treatment. By combining ruthenium metal complexes with therapeutic peptides, the approach seeks to enhance drug uptake in cancer cells and improve phototoxicity, even in low-oxygen environments.
One of the most severe limitations of current anticancer chemotherapy are the serious side effects caused by toxic drugs affecting not only tumors but also healthy organs.
Local activation of drugs by light irradiation of the tumor is a promising approach to control where the toxicity is delivered.
Metal complexes are well suited for photoactivated chemotherapy, but their activation wavelength is often too low to afford high tissue penetration of light; also, their ability to enter cancer cells…
UNIVERSITEIT LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
